The success of Sildenafil initially fueled a boom for the drug industry, but recent changes present a murky scenario for those considering a stake. Generic alternatives are reducing earnings, and ongoing litigation add more risk to the landscape. While specific companies might still benefit from related offerings, the general direction suggests a c